Navigation Links
Vasogen Provides Update on ACCLAIM II Program
Date:3/3/2008

tage clinical development for the treatment of chronic heart failure in the United States. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead candidate from this new class of drugs.

Certain statements contained in this press release, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct addition
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... ... Apex Therapeutics announced today that company CEO, David Broecker provided a company update ... took place on Tuesday, June 16 and provided an update on the achievement of ... of pancreatic cancer. A copy of the company overview can be found on ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... , Study will provide new insights on mechanics of fecal microbiota transplantation in ... partnership to study the microbiome of patients undergoing fecal microbiota transplantation (FMT) as ...
(Date:6/30/2015)... June 30, 2015  The University of California, ... (CCE/Bio) and UC San Diego Extension announced their ... held Aug.  12 – 14, 2015, at UC ... workshop provides an intense exposure to best practices ... is well-suited to biologists, process engineers and business ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2
... with diarrhea and intestinal function may provide a new ... other neuropsychiatric disorders, according to a team of scientists ... in Science . Scientists have ... receptor protein, guanylyl cyclase-C (GC-C) for its role in ...
... of toxic mercury are released into the environment every year. ... into toxic methyl mercury, and enters the food chain ending ... BioMed Central,s open access journal BMC Biotechnology , showcases ... high levels of mercury but are also able to mop ...
... Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for ... business update. Second Quarter Financial ResultsNet sales ... increase of 50 percent compared with $5.1 million for the ... 59 percent of net sales, compared with gross profit of ...
Cached Biology Technology:Intestinal protein may have role in ADHD, other neurological disorders 2Transgenomic Reports Second Quarter Financial Results 2Transgenomic Reports Second Quarter Financial Results 3Transgenomic Reports Second Quarter Financial Results 4Transgenomic Reports Second Quarter Financial Results 5Transgenomic Reports Second Quarter Financial Results 6Transgenomic Reports Second Quarter Financial Results 7Transgenomic Reports Second Quarter Financial Results 8Transgenomic Reports Second Quarter Financial Results 9
(Date:6/18/2015)... YORK , June 18, 2015 This ... US$ Million by the following Product Segments, which includes ... Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric ... the US, Canada , ... Asia-Pacific , Latin America ...
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... touch fingerprint sensors in the company,s portfolio from one of ... are planned to mainly take place during the third quarter ... Asia . Jörgen Lantto, CEO ... of    the   growing interest from smartphone OEMs in ...
Breaking Biology News(10 mins):Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... has proven up to 88 per cent effective in ... of G study. The study appears in the ... It,s a crucial finding because the health product industry ... and environmental implications, says study author Mehrdad Hajibabaei. ...
... Mich. A team of researchers at Michigan State University ... functions. The results, published in the current issue of ... that decodes how E. coli bacteria figured out ... extra course of citrate. "It,s pretty nifty to see ...
... 2012-- Researchers have successfully developed a stable population of ... grown in large quantities in the laboratory and that ... types needed throughout the body. This powerful new research ... and disease is described in an article published in ...
Cached Biology News:Study: DNA barcoding can ID natural health products 2Evolution is as complicated as 1-2-3 2
GOAT ANTI SLI...
ANTI L-DOPA...
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
Recombinant Rat CINC-2 alpha, CF...
Biology Products: